Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Construction of bioengineered hepatic tissue derived from human umbilical cord mesenchymal stem cells via aggregation culture in porcine decellularized liver scaffolds
Li, Yi , Wu, Qiong , Wang, Yujia , Li, Li , Shi, Yujun , Bu, Hong , Chen, Fei , Bao, Ji

Mayo Clinic

Xenotransplantation | January 27, 2017 | Volume: 24 | Issue: 1 | Pages: No page available

10.1111/xen.12285 | PMID 28127796 Get It

AbstractBackgroundAn individualized, tissue‐engineered liver suitable for transplanting into a patient with liver disease would be of great benefit to the patient and the healthcare system. The tissue‐engineered liver would possess the functions of the original healthy organ. Two fields of study, (i) using decellularized tissue as cell scaffolding, and (ii) stem cell differentiation into functional cells, are coming together to make this concept feasible. The decellularized liver scaffolds (DLS) can interact with cells to promote cell differentiation and signal transduction and three‐dimensional (3D) stem cell aggregations can maintain the phenotypes and improve functions of stem cells after differentiation by undergoing cell‐cell contact. Although the effects of DLS and stem cell aggregation culture have been intensively studied, few observations about the interaction between the two have been achieved.MethodsWe established a method that combines the use of decellularized liver scaffolds and aggregation culture of MSCs (3D‐DLS) and explored the effects of the two on hepatic differentiation of human umbilical cord mesenchymal stem cells (hUC‐MSCs) in bioengineered hepatic tissue.ResultsA higher percentage of albumin‐producing cells, higher levels of liver‐specific transcripts, higher urea cycle‐related transcripts, and lower levels of stem cell‐specific transcripts were observed in the 3D‐DLS group when compared to that of hUC‐MSCs in monolayer culture (2D), aggregation culture (3D), monolayer on DLS culture (2D‐DLS). The gene arrays also indicated that 3D‐DLS induced the differentiation from the hUC‐MSC phenotype to the PHH phenotype. Liver‐specific proteins albumin, CK‐18, and glycogen storage were highly positive in the 3D‐DLS group. Albumin secretion and ammonia conversion to urea were more effective with a higher cell survival rate in the 3D‐DLS group for 14 days.ConclusionThis DLS and aggregation combination culture system provides a novel method to improve hepatic differentiation, maintain phenotype of hepatocyte‐like cells and sustain survival for 14 days in vitro. This is a promising strategy to use to construct bioengineered hepatic tissue.
Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer’s Disease Genes in African Americans Identifies Novel PSEN Variants
N’Songo, Aurelie, Carrasquillo, Minerva M. , Wang, Xue , Nguyen, Thuy , Asmann, Yan W. , Younkin, Steven G., Allen, Mariet , Duara, Ranjan , Custo, María T. Greig, Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Asmann, Yan, Carrasquillo, Minerva M. , Duara, Ranjan

Mayo Clinic

Journal of Alzheimer’s Disease | January 20, 2017 | Volume: 56 | Issue: 4 | Pages: 1215-1222

10.3233/jad-161185 | PMID 28106563 Get It

We conducted a comprehensive screening of rare coding variants in an African American cohort to identify novel pathogenic mutations within the early-onset Alzheimer’s disease (EOAD) genes ( APP, PSEN1 , and PSEN2) in this understudied population. Whole-exome sequencing of 238 African American subjects identified 6 rare missense variants within the EOAD genes, which were observed in AD cases but never among controls. These variants were analyzed in an independent cohort of 300 African American subjects in which PSEN2 :NM_000447:exon5:c.T331C:p.Phe111Leu and PSEN1-minilin rs777923890 variants were again not observed, indicating that these novel rare variants, may contribute to AD risk in this population.
Immunogenicity of hepatic differentiated human umbilical cord mesenchymal stem cells promoted by porcine decellularized liver scaffolds
Li, Yi , Wu, Qiong , Wang, Yujia , Li, Li , Shi, Yujun , Bu, Hong , Bao, Ji , Bao, Ji , Chen, Fei

Mayo Clinic

Xenotransplantation | January 19, 2017 | Volume: 24 | Issue: 1 | Pages: No page available

10.1111/xen.12287 | PMID 28102609 Get It

AbstractCell‐based approaches, including hepatocyte transplantation and tissue‐engineered livers, offer promising alternatives and are expected to help support patients with liver diseases until liver transplantation or recovery via regeneration of the damaged liver. However, the success of cell therapies remains dependent on how well the cells are accepted after transplantation and is directly related to their degree of immunogenicity. In this study, hepatic differentiation of human umbilical cord mesenchymal stem cells (hUC‐MSCs) was induced in the traditional monolayer (2D) culture and newly established three‐dimensional (3D) aggregation culture with the porcine decellularized liver scaffold (DLS) system (3D‐DLS). We investigated the immunogenicity of these hepatocyte‐like cells in vitro. We found that monolayer hepatic differentiated hUC‐MSCs expressed higher levels of human leukocyte antigen‐DR (HLA‐DR) (P<.05) and lost the ability to inhibit lymphocyte proliferation (P<.05), in association with a lower level of prostaglandin E2 (PGE2) (P<.05) and a higher level of interferon‐γ (IFN‐γ) (P<.05) secretion, compared to undifferentiated hUC‐MSCs. The hepatocyte‐like cells differentiated in the 3D‐DLS system did not show an elevation of MHC‐II (P>.05), or cause obvious lymphocytes proliferation, and demonstrated more PGE2 (P<.05) and less IFN‐γ (P<.05) secretion. Hepatocyte‐like cells in the 3D‐DLS system presented a lower immunogenic phenotype than the 2D culture in vitro. Hepatocyte‐like cells in 3D‐DLS system also performed a higher immunosuppressive capacity than 2D culture.
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems
Luzum, Jasmine A. , Pakyz, R E, Elsey, AR, Haidar, Cyrine E. , Peterson, JF, Whirl‐Carrillo, Michelle , Handelman, SK, Palmer, Kathleen , Pulley, JM, Beller, Michael, Schildcrout, JS, Field, JR, Weitzel, KW, Cooper‐DeHoff, RM, Cavallari, Larisa H. , O'Donnell, PH, Altman, Russ B. , Pereira, Naveen L. , Ratain, MJ, Roden, DM, Embi, PJ, Klein, Teri E. , Johnson, JA, Relling, MV, Wang, L, Weinshilboum, RM, Freimuth, Robert R. , Johnson, Julie A. , Peterson, Josh F. , Schildcrout, Jonathan S. , Elsey, Amanda R., Peterson, JF, Weitzel, KW, Cooper-DeHoff, RM, Ratain, Mark J. , Roden, DM, Sadée, Wolfgang , Relling, Mary V. , Shuldiner, Alan R. , Schildcrout, Jonathan S , Whirl-Carrillo, Michelle , Freimuth, Robert R , Peterson, Josh F , Cavallari, Larisa H , Luzum, Jasmine A , Klein, Teri E

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 16, 2017 | Volume: 102 | Issue: 3 | Pages: 502-510

10.1002/cpt.630 | PMID 28090649 Get It

Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real‐world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene–drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.
Improving uniformity in brain death determination policies over time
Wang, Hilary H., Varelas, Panayiotis N. , Henderson, Galen V., Greer, David M. , Wijdicks, Eelco F. M. , Greer, David Matthew

Mayo Clinic

Neurology | January 12, 2017 | Volume: 88 | Issue: 6 | Pages: 562-568

10.1212/wnl.0000000000003597 | PMID 28077490 Get It

Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Dyck, Peter J., Dyck, Peter J., Kincaid, John C., Dyck, P. James B. , Chaudhry, Vinay , Goyal, Namita , Alves, Christina , Salhi, Hayet, Wiesman, Janice F. , Labeyrie, Céline , Robinson‐Papp, Jessica , Cardoso, Márcio , Laurá, Matilde , Ruzhansky, Katherine , Cortese, Andrea , Brannagan, Thomas H., Khoury, Julie, Khella, Sami, Ferreira, João , Wang, Annabel K., Pinto, Marcus Vinícius , Ayache, Samar S. , Benson, Merrill D., Coelho, Teresa , Polydefkis, Michael , Gorevic, Peter D., Planté‐Bordeneuve, Violaine , Whelan, Carol , Merlini, Giampaolo , Drachman, Brian, Conceição, Isabel , Klein, Christopher J. , Ackermann, Elizabeth J., Hughes, Steven G. , Mauermann, Michelle L. , Bergemann, R , Lodermeier, Karen A., Davies, Jenny L., Carter, Rickey E. , Litchy, William J. , Dyck, Peter J., Dyck, Peter J., Waddington‐Cruz, Márcia , Berk, John L. , Adams, David , Heitner, Stephen B. , Gertz, Morie A. , Merlini, Giampaolo , Pinto, Marcus V , Klein, Christopher J , Brannagan, T H , Carter, Rickey E , Conceição, Isabel , Mauermann, Michelle L

Mayo Clinic

Muscle & Nerve | January 7, 2017 | Volume: 56 | Issue: 5 | Pages: 901-911

10.1002/mus.25563 | PMID 28063170 Get It

ABSTRACTIntroductionPolyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic tests (m+7Ionis), disability, and health scores were assessed in baseline evaluations of 100 patients entered into an oligonucleotide familial amyloidotic polyneuropathy (FAP) trial.MethodsWe assessed: (1) Proficiency of grading neurologic signs and correlation with neurophysiologic tests, and (2) clinometric performance of modified NIS+7 neurophysiologic tests (mNIS+7Ionis) and its subscores and correlation with disability and health scores.ResultsThe mNIS+7Ionis sensitively detected, characterized, and broadly scaled diverse polyneuropathy impairments. Polyneuropathy signs (NIS and subscores) correlated with neurophysiology tests, disability, and health scores. Smart Somatotopic Quantitative Sensation Testing of heat as pain 5 provided a needed measure of small fiber involvement not adequately assessed by other tests.ConclusionsSpecially trained neurologists accurately assessed neuropathy signs as compared to referenced neurophysiologic tests. The score, mNIS+7Ionis, broadly detected, characterized, and scaled polyneuropathy abnormality in FAP, which correlated with disability and health scores. Muscle Nerve 56: 901–911, 2017
Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell–like spheroids, and tumor xenografts through multiple cell signaling pathways
Bijangi‐Vishehsaraei, Khadijeh , Saadatzadeh, M. Reza , Nguyen, Angie, Kamocka, Malgorzata M. , Cai, Wenjing , Cohen‐Gadol, Aaron , Halum, Stacey L. , Pollok, Karen E. , Safa, Ahmad R., Wang, Haiyan , Cai, Wenjing, Sarkaria, Jann N.

Mayo Clinic

Journal of Neurosurgery | January 6, 2017 | Volume: 127 | Issue: 6 | Pages: 1219-1230

10.3171/2016.8.jns161197 | PMID 28059653 Get It

OBJECTIVE Defects in the apoptotic machinery and augmented survival signals contribute to drug resistance in glioblastoma (GBM). Moreover, another complexity related to GBM treatment is the concept that GBM development and recurrence may arise from the expression of GBM stem cells (GSCs). Therefore, the use of a multifaceted approach or multitargeted agents that affect specific tumor cell characteristics will likely be necessary to successfully eradicate GBM. The objective of this study was to investigate the usefulness of sulforaphane (SFN)—a constituent of cruciferous vegetables with a multitargeted effect—as a therapeutic agent for GBM. METHODS The inhibitory effects of SFN on established cell lines, early primary cultures, CD133-positive GSCs, GSC-derived spheroids, and GBM xenografts were evaluated using various methods, including GSC isolation and the sphere-forming assay, analysis of reactive oxygen species (ROS) and apoptosis, cell growth inhibition assay, comet assays for assessing SFN-triggered DNA damage, confocal microscopy, Western blot analysis, and the determination of in vivo efficacy as assessed in human GBM xenograft models. RESULTS SFN triggered the significant inhibition of cell survival and induced apoptotic cell death, which was associated with caspase 3 and caspase 7 activation. Moreover, SFN triggered the formation of mitochondrial ROS, and SFN-triggered cell death was ROS dependent. Comet assays revealed that SFN increased single- and double-strand DNA breaks in GBM. Compared with the vehicle control cells, a significantly higher amount of γ-H2AX foci correlated with an increase in DNA double-strand breaks in the SFN-treated samples. Furthermore, SFN robustly inhibited the growth of GBM cell–induced cell death in established cell cultures and early-passage primary cultures and, most importantly, was effective in eliminating GSCs, which play a major role in drug resistance and disease recurrence. In vivo studies revealed that SFN administration at 100 mg/kg for 5-day cycles repeated for 3 weeks significantly decreased the growth of ectopic xenografts that were established from the early passage of primary cultures of GBM10. CONCLUSIONS These results suggest that SFN is a potent anti-GBM agent that targets several apoptosis and cell survival pathways and further preclinical and clinical studies may prove that SFN alone or in combination with other therapies may be potentially useful for GBM therapy.
Generalized ensemble model for document ranking in information retrieval
Wang, Yanshan, Choi, In-Chan, Liu, Hongfang, Wang, Yanshan , Wang, Yanshan, Choi, In-Chan, Liu, Hongfang, Wang, Yanshan

Mayo Clinic

Computer Science and Information Systems | December 30, 2016 | Volume: 14 | Issue: 1 | Pages: 123-151

10.2298/csis160229042w Get It

A generalized ensemble model (gEnM) for document ranking is proposed in this paper. The gEnM linearly combines the document retrieval models and tries to retrieve relevant documents at high positions. In order to obtain the optimal linear combination of multiple document retrieval models or rankers, an optimization program is formulated by directly maximizing the mean average precision. Both supervised and unsupervised learning algorithms are presented to solve this program. For the supervised scheme, two approaches are considered based on the data setting, namely batch and online setting. In the batch setting, we propose a revised Newton?s algorithm, gEnM.BAT, by approximating the derivative and Hessian matrix. In the online setting, we advocate a stochastic gradient descent (SGD) based algorithm-gEnM.ON. As for the unsupervised scheme, an unsupervised ensemble model (UnsEnM) by iteratively co-learning from each constituent ranker is presented. Experimental study on benchmark data sets verifies the effectiveness of the proposed algorithms. Therefore, with appropriate algorithms, the gEnM is a viable option in diverse practical information retrieval applications.
MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2
Gregory, Philip A. , Fernandes, Rayzel C. , Denis, Iza , Wang, Qingqing , Townley, Scott L. , Zhao, Shuang G. , Hanson, Adrienne R. , Pickering, Marie , Armstrong, Heather , Lokman, Noor A. , Ebrahimie, Esmaeil , Jenkins, Robert B. , Karnes, R. Jeffrey , Ross, Ashley E. , Den, Robert B. , Klein, Eric A. , Ramshaw, Hayley S. , Williams, Elizabeth D. , Zoubeidi, Amina , Goodall, Gregory J. , Feng, Felix Y. , Butler, Lisa M. , Tilley, Wayne D. , Selth, Luke A. , Das, Rajdeep , Townley, Scott L. , Zhao, Shuang G , Davicioni, Elai , N., Kim , Den, Robert B , Klein, Eric A

Mayo Clinic

Cancer Research | December 23, 2016 | Volume: 77 | Issue: 4 | Pages: 1021-1034

10.1158/0008-5472.can-16-2529 | PMID 28011622 Get It

Abstract Serum levels of miR-194 have been reported to predict prostate cancer recurrence after surgery, but its functional contributions to this disease have not been studied. Herein, it is demonstrated that miR-194 is a driver of prostate cancer metastasis. Prostate tissue levels of miR-194 were associated with disease aggressiveness and poor outcome. Ectopic delivery of miR-194 stimulated migration, invasion, and epithelial–mesenchymal transition in human prostate cancer cell lines, and stable overexpression of miR-194 enhanced metastasis of intravenous and intraprostatic tumor xenografts. Conversely, inhibition of miR-194 activity suppressed the invasive capacity of prostate cancer cell lines in vitro and in vivo. Mechanistic investigations identified the ubiquitin ligase suppressor of cytokine signaling 2 (SOCS2) as a direct, biologically relevant target of miR-194 in prostate cancer. Low levels of SOCS2 correlated strongly with disease recurrence and metastasis in clinical specimens. SOCS2 downregulation recapitulated miR-194–driven metastatic phenotypes, whereas overexpression of a nontargetable SOCS2 reduced miR-194–stimulated invasion. Targeting of SOCS2 by miR-194 resulted in derepression of the oncogenic kinases FLT3 and JAK2, leading to enhanced ERK and STAT3 signaling. Pharmacologic inhibition of ERK and JAK/STAT pathways reversed miR-194–driven phenotypes. The GATA2 transcription factor was identified as an upstream regulator of miR-194, consistent with a strong concordance between GATA2 and miR-194 levels in clinical specimens. Overall, these results offer new insights into the molecular mechanisms of metastatic progression in prostate cancer. Cancer Res; 77(4); 1021–34. ©2016 AACR.